| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
N-Methylpiperazine-d8 hydrochloride is an isotope-labeled internal standard and does not have a pharmacological target. The unlabeled N-methylpiperazine is a chemical building block used in pharmaceutical synthesis and does not have a specific biological target. The deuterated form is used for analytical purposes rather than as a therapeutic agent.
|
|---|---|
| ln Vitro |
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Studies involving the human use of drugs labeled with deuterium suggest that these compounds may offer some advantages when compared with their nondeuterated counterparts. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs. Deutetrabenazine is the first deuterated drug to receive Food and Drug Administration approval. This deuterated form of the drug tetrabenazine is indicated for the treatment of chorea associated with Huntington's disease as well as tardive dyskinesia. Ongoing clinical trials suggest that a number of other deuterated compounds are being evaluated for the treatment of human diseases and not merely as research tools.
As a deuterated internal standard, N-Methylpiperazine-d8 hydrochloride itself does not exhibit biological activity. Its utility lies in its use as an analytical standard for the quantification of N-methylpiperazine in biological and pharmaceutical samples. The deuterium labeling provides a mass shift that enables accurate quantification by mass spectrometry without chromatographic interference from the unlabeled compound. |
| ln Vivo |
Deuterated compounds may, in some cases, offer advantages over nondeuterated forms, often through alterations in clearance. Deuteration may also redirect metabolic pathways in directions that reduce toxicities. The approval of additional deuterated compounds may soon follow. Clinicians will need to be familiar with the dosing, efficacy, potential side effects, and unique metabolic profiles of these new entities.
N-Methylpiperazine-d8 hydrochloride is not a therapeutic compound and is not evaluated for in vivo activity. Its primary application is in analytical chemistry and pharmaceutical development, where it is used as an internal standard for the quantification of N-methylpiperazine in biological samples. The compound is not administered to animals for pharmacological studies. |
| Enzyme Assay |
Non-cell-based protocols for N-Methylpiperazine-d8 hydrochloride involve LC-MS/MS or GC-MS analysis. A typical workflow includes: sample preparation (protein precipitation, liquid-liquid extraction, or solid-phase extraction), chromatographic separation on a suitable column, and MS/MS detection in MRM mode using the characteristic mass transitions of the deuterated compound. The deuterated internal standard is added to samples prior to extraction to correct for matrix effects and extraction recovery.
|
| Cell Assay |
Cellular assays are not applicable to N-Methylpiperazine-d8 hydrochloride as it is an analytical standard. The compound is not used in cell-based studies to assess biological activity. Its primary application is in analytical chemistry for the quantification of N-methylpiperazine in biological and pharmaceutical samples.
|
| Animal Protocol |
In vivo animal studies with N-Methylpiperazine-d8 hydrochloride are not conducted as it is an analytical standard. The compound is not administered to animals for pharmacological or toxicological studies. Its use is limited to analytical applications in pharmaceutical development and research.
|
| ADME/Pharmacokinetics |
As an isotope-labeled internal standard, N-Methylpiperazine-d8 hydrochloride has no pharmacokinetic properties of its own. The unlabeled N-methylpiperazine is a small molecule with a molecular weight of 100.16 g/mol that is used as a chemical building block. The deuterated form is used for analytical quantification and is not evaluated for pharmacokinetic parameters.
|
| Toxicity/Toxicokinetics |
As a research-use isotope-labeled compound, N-Methylpiperazine-d8 hydrochloride is not intended for human therapeutic use, and toxicological data are not applicable. Standard laboratory safety precautions should be followed when handling the compound. The compound is typically stored at room temperature and protected from moisture.
|
| References | |
| Additional Infomation |
N-Methylpiperazine-d8 hydrochloride is a stable isotope-labeled internal standard for the quantification of N-methylpiperazine in biological and pharmaceutical samples. N-Methylpiperazine is a widely used chemical building block in pharmaceutical synthesis, and its quantification is important for drug development and quality control. The deuterated form provides accurate quantification by mass spectrometry, with the eight deuterium atoms providing a mass shift of 8 Da from the unlabeled compound.
|
| Molecular Formula |
C5H6D8CL2N2
|
|---|---|
| Molecular Weight |
181.13
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5209 mL | 27.6045 mL | 55.2090 mL | |
| 5 mM | 1.1042 mL | 5.5209 mL | 11.0418 mL | |
| 10 mM | 0.5521 mL | 2.7604 mL | 5.5209 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
